Nearly a decade ago we published the blogpost “Pre-Approval Design Defects – No Such Thing.”  As we discussed, “pre-approval” design (later joined by warning) claims were a transparent preemption dodge.  No such claims had ever been advanced before the Supreme Court’s holdings in the generic drug preemption cases (Mensing/Bartlett)…